+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rx-to-OTC Switches Market

  • ID: 5440410
  • Report
  • July 2021
  • Region: Global
  • 237 Pages
  • Future Market Insights

FEATURED COMPANIES

  • Alcon
  • Arbor Pharmaceuticals
  • Astrazeneca
  • Bayer AG
  • Galderma SA
  • GlaxoSmithKline plc.
Rx-to-OTC switches refer to the transition from proven prescription drugs to nonprescription, OTC status. According to this report, the global Rx-to-OTC switches market was valued at US$ 33 Bn in 2020 and is predicted to expand at a CAGR of over 5% during the forecast period (2021-2031).

Scientifically, it is a rigorous and highly regulated process that allows consumers to purchase OTC access to a growing range of medicines. For a medicine to be granted under OTC status, it must comply with the regulatory standards associated with its efficacy, have a wide safety margin, and bolster labelling to ensure proper usage of the product.

The increasing prevalence of diseases with common self-treatable symptoms, such as cold and flu, headaches, allergies, and others has fuelled the demand for OTC drugs. Thus, growing sales of nonprescription drugs have pushed pharmaceutical companies to focus on Rx to OTC switches to meet customer needs thereby gaining high revenue in the market.

It was observed in 2020, Rx-to-OTC activity was driven by growing regulatory approvals and increased OTC sales. The COVID-19 outbreak has restricted patients to visit hospitals and clinics suffering from common illnesses. Consequently, delays in prescribed medication have shifted the customer preference towards the OTC drug consumption. As a result, the COVID 19 outbreak bolstered the demand for OTC products, which in turn has supported the adoption of Rx-to-OTC switches.

The Food and Drug Administration (FDA) introduced the non-prescription safe use regulatory expansion (NSURE) panel in 2013 that has supported a new wave of Rx-to-OTC switches, with a focus on creating conditions for switches in new therapeutic classes.

The introduction of the panel aimed to promote switches which had gained consumer attention, which in turn has aided the demand for the OTC drugs in the market.

Key Takeaways from Rx-to-OTC Switches Market Study


  • Allergy and respiratory drugs are anticipated to gain a revenue share of more than 25% with a CAGR of 5.7% owing to the rising prevalence of lifestyle-based ailments.
  • Retail pharmacies are anticipated to grow at a CAGR of 5.1% over the forecast period owing to the rise of e-commerce and the procurement of cost-effective medicines.
  • The U.K. holds the lead in Europe, holding a share of over 33% owing to the implementation of favorable government policies.
  • The U.S. will account for over 77% of the North America market by 2031, supported by a matured healthcare and pharmaceutical sector and favorable reimbursement policies.
  • China is the largest and fastest growing market in East Asia estimated to account for close to 49% of the global market, owing to the country’s large-scale pharmaceutical requirements.

Who is Winning?


Rx to OTC switches have led the pharmaceutical companies to shift focus from patients to consumers in terms of end users. In addition to strategic collaborations, acquisitions, expansion, product launches, agreements and research sponsorships are the key strategies adopted by manufacturers to expand their research and development (R&D) capabilities increasing sales in wider geographical base to strengthen product portfolios in the Rx-to-OTC switches market.

For instance, in January 2021, Boehringer Ingelheim entered into a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D).
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alcon
  • Arbor Pharmaceuticals
  • Astrazeneca
  • Bayer AG
  • Galderma SA
  • GlaxoSmithKline plc.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends
3.1. Key Trends Impacting the Market

4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Outlook
4.1.3. Per Capita Healthcare Expenditure Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Growing Demand and Sales for OTC Medication
4.2.2. Cost of OTC Medication
4.2.3. Availability of OTC Drugs
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis

5. COVID19 Crisis Analysis
5.1. Current COVID19 Probable Future Impact
5.2. Current GDP Projection and Probable Impact
5.3. Current Economic Projection as compared to 2008 Economic analysis
5.4. COVID19 and Impact Analysis
5.4.1.1. Revenue By Drug Categories
5.4.1.2. Revenue By Distribution Channel
5.4.1.3. Revenue By Region
5.5. 2020 Market Scenario
5.6. Recovery Scenario - Short term, Midterm and Long Term Impact

6. Key Success Factors
6.1. Business Model
6.2. Key Regulations
6.3. Go-To-Market Strategy
6.4. Adoption Rate of OTC drugs, By Region

7. Global Rx-to-OTC Switches Market Demand (in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Drug Category
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug Category, 2016-2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Category, 2021-2031
8.3.1. Allergy and Respiratory
8.3.2. Fungal Infections & Other infections
8.3.3. Overactive Bladder
8.3.4. Oral Contraceptives
8.3.5. Gastrointestinal Drugs
8.3.6. Hair Loss Treatments
8.3.7. Smoking Cessation
8.3.8. Analgesic, Inflammation and pain management
8.3.9. Others (lice, Acne, weight loss, laxative)
8.4. Market Attractiveness Analysis By Drug Category

9. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Drug Stores
9.3.4. Online Pharmacies
9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis By Region

11. North America Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Category
11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis

12. Latin America Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Category
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis

13. Europe Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug Category
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis

14. East Asia Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
14.3. Current and Future Market Size (US$ Mn) Trend and Analysis and Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Drug Category
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis

15. South Asia Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Drug Category
15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis

16. Oceania Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Category
16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2020
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. Northern Africa
17.3.1.4. South Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Drug Category
17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis

18. Key and Emerging Countries Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. U.S. Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.2.1. By Drug Category
18.2.2. By Distribution Channel
18.3. Canada Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.3.1. By Drug Category
18.3.2. By Distribution Channel
18.4. Mexico Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.4.1. By Drug Category
18.4.2. By Distribution Channel
18.5. Brazil Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.5.1. By Drug Category
18.5.2. By Distribution Channel
18.6. U.K. Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.6.1. By Drug Category
18.6.2. By Distribution Channel
18.7. Germany Rx-to-OTC Switches Market Analysis
18.7.1. By Drug Category
18.7.2. By Distribution Channel
18.8. France Rx-to-OTC Switches Market Analysis
18.8.1. By Drug Category
18.8.2. By Distribution Channel
18.9. Italy Rx-to-OTC Switches Market Analysis
18.9.1. By Drug Category
18.9.2. By Distribution Channel
18.10. Spain Rx-to-OTC Switches Market Analysis
18.10.1. By Drug Category
18.10.2. By Distribution Channel
18.11. Russia Rx-to-OTC Switches Market Analysis
18.11.1. By Drug Category
18.11.2. By Distribution Channel
18.12. China Rx-to-OTC Switches Market Analysis
18.12.1. By Drug Category
18.12.2. By Distribution Channel
18.13. Japan Rx-to-OTC Switches Market Analysis
18.13.1. By Drug Category
18.13.2. By Distribution Channel
18.14. South Korea Rx-to-OTC Switches Market Analysis
18.14.1. By Drug Category
18.14.2. By Distribution Channel
18.15. India Rx-to-OTC Switches Market Analysis
18.15.1. By Drug Category
18.15.2. By Distribution Channel
18.16. Thailand Rx-to-OTC Switches Market Analysis
18.16.1. By Drug Category
18.16.2. By Distribution Channel
18.17. Indonesia Rx-to-OTC Switches Market Analysis
18.17.1. By Drug Category
18.17.2. By Distribution Channel
18.18. Malaysia Rx-to-OTC Switches Market Analysis
18.18.1. By Drug Category
18.18.2. By Distribution Channel
18.19. Australia Rx-to-OTC Switches Market Analysis
18.19.1. By Drug Category
18.19.2. By Distribution Channel
18.20. New Zealand Rx-to-OTC Switches Market Analysis
18.20.1. By Drug Category
18.20.2. By Distribution Channel
18.21. GCC Countries Rx-to-OTC Switches Market Analysis
18.21.1. By Drug Category
18.21.2. By Distribution Channel
18.22. South Africa Rx-to-OTC Switches Market Analysis
18.22.1. By Drug Category
18.22.2. By Distribution Channel
18.23. Turkey Rx-to-OTC Switches Market Analysis
18.23.1. By Drug Category
18.23.2. By Distribution Channel

19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Concentration

20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. GlaxoSmithKline plc.
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Profitability by Market Segments (Product/Channel/Region)
20.2.1.4. Sales Footprint
20.2.1.5. Strategy Overview
20.2.1.5.1. Marketing Strategy
20.2.1.5.2. Product Strategy
20.2.1.5.3. Channel Strategy
20.2.2. Astrazeneca
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. Profitability by Market Segments (Product/Channel/Region)
20.2.2.4. Sales Footprint
20.2.2.5. Strategy Overview
20.2.2.5.1. Marketing Strategy
20.2.2.5.2. Product Strategy
20.2.2.5.3. Channel Strategy
20.2.3. Merck KGaA
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. Profitability by Market Segments (Product/Channel/Region)
20.2.3.4. Sales Footprint
20.2.3.5. Strategy Overview
20.2.3.5.1. Marketing Strategy
20.2.3.5.2. Product Strategy
20.2.3.5.3. Channel Strategy
20.2.4. Johnson & Johnson
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. Profitability by Market Segments (Product/Channel/Region)
20.2.4.4. Sales Footprint
20.2.4.5. Strategy Overview
20.2.4.5.1. Marketing Strategy
20.2.4.5.2. Product Strategy
20.2.4.5.3. Channel Strategy
20.2.5. Bayer AG
20.2.5.1. Overview
20.2.5.2. Product Portfolio
20.2.5.3. Profitability by Market Segments (Product/Channel/Region)
20.2.5.4. Sales Footprint
20.2.5.5. Strategy Overview
20.2.5.5.1. Marketing Strategy
20.2.5.5.2. Product Strategy
20.2.5.5.3. Channel Strategy
20.2.6. Sanofi
20.2.6.1. Overview
20.2.6.2. Product Portfolio
20.2.6.3. Profitability by Market Segments (Product/Channel/Region)
20.2.6.4. Sales Footprint
20.2.6.5. Strategy Overview
20.2.6.5.1. Marketing Strategy
20.2.6.5.2. Product Strategy
20.2.6.5.3. Channel Strategy
20.2.7. Boehringer Ingelheim Consumer Healthcare
20.2.7.1. Overview
20.2.7.2. Product Portfolio
20.2.7.3. Profitability by Market Segments (Product/Channel/Region)
20.2.7.4. Sales Footprint
20.2.7.5. Strategy Overview
20.2.7.5.1. Marketing Strategy
20.2.7.5.2. Product Strategy
20.2.7.5.3. Channel Strategy
20.2.8. Bausch and Lomb (A Subsidiary of Bausch Health)
20.2.8.1. Overview
20.2.8.2. Product Portfolio
20.2.8.3. Profitability by Market Segments (Product/Channel/Region)
20.2.8.4. Sales Footprint
20.2.8.5. Strategy Overview
20.2.8.5.1. Marketing Strategy
20.2.8.5.2. Product Strategy
20.2.8.5.3. Channel Strategy
20.2.9. Galderma SA
20.2.9.1. Overview
20.2.9.2. Product Portfolio
20.2.9.3. Profitability by Market Segments (Product/Channel/Region)
20.2.9.4. Sales Footprint
20.2.9.5. Strategy Overview
20.2.9.5.1. Marketing Strategy
20.2.9.5.2. Product Strategy
20.2.9.5.3. Channel Strategy
20.2.10. Alcon
20.2.10.1. Overview
20.2.10.2. Product Portfolio
20.2.10.3. Profitability by Market Segments (Product/Channel/Region)
20.2.10.4. Sales Footprint
20.2.10.5. Strategy Overview
20.2.10.5.1. Marketing Strategy
20.2.10.5.2. Product Strategy
20.2.10.5.3. Channel Strategy
20.2.11. Arbor Pharmaceuticals
20.2.11.1. Overview
20.2.11.2. Product Portfolio
20.2.11.3. Profitability by Market Segments (Product/Channel/Region)
20.2.11.4. Sales Footprint
20.2.11.5. Strategy Overview
20.2.11.5.1. Marketing Strategy
20.2.11.5.2. Product Strategy
20.2.11.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology
Note: Product cover images may vary from those shown
  • GlaxoSmithKline plc.
  • Astrazeneca
  • Merck KGaA
  • Johnson & Johnson
  • Bayer AG
  • Sanofi
  • Boehringer Ingelheim Consumer Healthcare
  • Bausch and Lomb (A Subsidiary of Bausch Health)
  • Galderma SA
  • Alcon
  • Arbor Pharmaceuticals
Note: Product cover images may vary from those shown